In this respect, more studies with a prospective design and a variety of clinical characteristics will be needed to further evaluate possible applicability of HMGB1, sRAGE and the HMGB1/sRAGE ratio in ovarian cancer. This evidence concerns the gene HMGB1 and ovarian cancer.